Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Place your order under the Bid, someone will buy them
Jesus. How to dump the shares being held is a nightmare. Gonna need to put ask for .01 and dump this whole load of shat.
Yep thats credible isn't it..... Not
The scam goes on. I guess there might be someone out there who would read this scammers history and all of the promises made over the years and STILL think it's worth a punt.
Ya ok
In addition, earlier this month, our CEO, Randall McCoy began discussions with Saudi Arabian ministers related to potential joint venture opportunities.
From 10Q
Overview
The company’s major objective for 2018 remains to secure the required funding to finalize some additional requirements of the IND application, and begin the clinical trials. It is estimated that the cost to finalize the IND will be approximately 1.5 million dollars, and the cost to complete Phase 1 of the clinical trial will be approximately 2 million dollars. As previously reported, our goal in obtaining this funding has been to minimize shareholders' dilution as much as possible. Consequently, we are primarily pursuing financing through the issuance of a debt instrument and international licensing agreements. We have been working on a significant debt financing over the last 6 months and hope to complete this form of financing during the coming quarter. In addition, earlier this month, our CEO, Randall McCoy began discussions with Saudi Arabian ministers related to potential joint venture opportunities.
I think it's time to dump the couple hundred thousand shares I had. What a SCAM this foul smelling waste of time was.
No. They've moved onto another post or blog somewhere. Touting and scamming I'm sure there won't be a peep on here.SEC does need a call from a simple investor to have the curtain pulled back with a serious investigation of what has and hasn't been going on let's say
Yes, Applevision, scumbag is a good description, but no-one can say the signs have not been clear for a long time, and available to see under any reasonable due diligence. The associations with other scumbags are pretty clear as well, Discala etc.
No doubt there will be a new statement from Nicole/McCoy saying how imminent great success is, and it is only just over the horizon etc etc. But surely now even the most naieve investor would be super sceptical. I can't see how this is escaping the attention of the SEC?
Whittling down shares slow and controlled dive to zero value. What a scumbag
Someone's keeping it floating. Question is why?
People are waking up to this scam. As far as I can tell, none of McCoys claims have ever been credible, but I guess you only have to fool some people, some of the time. The research he claims to prove benefits was shut down by FDA, and is about 10+ years old and well outdated anyway. He doesn't have a product, or any "special" approvals from FDA. If his product or IP was as great as he claims, it seems unlikely he would still be operating from his garage all these years later. His associations with Discala defendants is well known, and who would fall of their chair if it became known that Discala companies financed the launch of Reginicin and remain involved?
It's a fundamental shame that at this point the stock is basically worthless and only redeemable as a total loss.
Basically a complete write off to a negligent C or S Corp with holdings that cannot be recouped or traded any time time in the future due to mishandling and misleading investors.
Don't hold your breath. There is nothing serious about this at all.
If this was taken seriously. Funding and a legitimate corporate address with lab space and trial space would be pending 36 months ago.
Absolute lack of knowledge on how a supposed CEO drives a company.
This is a scam and should be dusted. Listed owner is professional educator. They typically have notions of grandeur. But very rarely understand how the real world works.
10 years in the making from Windstar. Loss in court 3 years ago of property rights.
No urgency in getting anything done.
Just sucking off shares month to month to pay the water and electricity bill.
What a joke McCoy is playing.
Where is Nicole now? I am eagerly awaiting the latest and greatest rgin news for a serious source...
Should be a big day. Plenty of time has passed for funding to be followed through with. If what has been sold by RGIN on its site then BIO Tech should have been easily encouraged to be on board.
Is there a credible/plausible story on the current status of the product development plan. If you answer pls provide some evidence.
Yup .. 1st of the month. Bills due. Go figure. Piggybank. Not a legit company
Somebody dig a hole. This dog is dead.
So your leading investors to believe that the FDA is personally excited about something that is in desperate need.
If that was the unobscured truth. Then capital investment would be all over this. Ay the least offers from biotech companies that routinely have level space available would be readily awaiting.
None of this is true.
Your certainty has shifted. You don't seem to be the same person. Feels more like a desperate push to keep others inline to hold onto basically... Nothing.
I think you've bleed this for all you can. Tap your vast scholarly pension and collegiate tenure.
You have mislead and stroked this false sense of urgency, need and worth by the FDA which is patently false.
Sloppy misdealings to keep it alive.
Randy nows exactly what has to be done, I’m sure things are moving well with the funding, guys be patient have hope , I’m here just like all of you waiting for the big bubble to burst , this is a life saving technology, fda is very excited with this project, we should all think well and not down the company if you hav no idea on what’s happening, Good Luck To All That Believe and been patient
Not quite the end of the month. Randy doesn't need to trade out 10 or 20 K shares for bills. This is nothing more than a little Piggy Bank for just that. He can draw off this till death do he part. Big time scam. No news here folks... Look away nothing to see. Just another idealouge scam artist. Far to many other companies surpassing RGINs so called patented processes. That are going no where.
Nicole where are you. We are hanging on your every word....haven’t heard any of your bull shite for a while.
Just wait everyone, dont overreact. Nicole/Randy will be online very soon advising just how great things are shortly about to be and that we will all be rolling in cash imminently.
But in the real world, I guess there will be more suckers hanging on to hope that RGIN will one day be discovered, after all these years of scamming away in the shadows.
Nicole seems to be way off with her analysis
Wow lots of action.... Complete spiral downward. All that funding must be rolling in....
From a technical standpoint, its hard to say what is coming short term. But if I were an 8 ball, Id say the next move is .20 range +-
http://stockcharts.com/h-sc/ui?s=RGIN&p=D&yr=1&mn=3&dy=0&id=p10877718681
RGIN trades in the whackiest of ways. Some days not a single share passes through the ticker, some days 50-60 thousand shares, and that one day of dumping a big denomination.
News is coming someday, cultured skin is becoming popular. Whether or not RGIN makes it is another story, other companies are doing it.
How were they able to get a huge transaction like that done in one trade. I bet if we in retail tried to dump nearly 3M shares, the MMs would take a portion then drop the bid multiple times.
Overview
As we move into 2018, the Company will continue to pursue its goal of obtaining FDA approval for its product NovaDerm. The product is well positioned to enter clinical trials. At this point the most significant gating item is financing. We have been consistently working with several investor groups and we remain confident that the necessary funding will be secured.
NovaDerm is well positioned to enter clinical trials due to the following:
- NovaDerm has an extensive documented history of clinical research.
- Additional independent product research has demonstrated the products superiority.
- NovaDerm has been awarded Orphan Product Designation by the FDA, which indicates the value and humanitarian benefits of the product.
- The positive results of the Pre-IND Application meeting between the Company and the FDA, in which both parties fully agreed on a pathway forward to enter the clinical trials.
- The Company has entered into two critical contracts to secure Closed Herd collagen and to fabricate the collagen scaffolds, the platform on which NovaDerm is grown.
- The company has selected a Clinical Research Organization, (CRO), to assist in the management of the clinical trials and the Company has identified a Principal Lead Investigator, a medical advisor for the clinical trials.
- In conjunction with CRO, two clinical sites will be selected to host the clinical trials.
Based on our agreement with the FDA, the clinical trials call for 3 patients initially and then 7 additional patients. The entire episode of care is estimated to be 1-4 months, depending on the severity of the burn. NovaDerm’s protocol is similiar to that currently performed with split thickness allograph and other temporary skin substitutes. Therefore, there is no additional physician training required. The chance of an immune system rejection is greatly reduced because NovaDerm is produced from the patient’s own cells. Finally, patient recruitment should be very fast because it will require fewer patients because of it’s Orphan status. When NovaDerm is approved to start clinical trials, NovaDerm may be used by any of the 150 burn centers for Humanitarian Use as long as the burn center agrees to follow the clinical trial protocol on file with the IND.
As aforementioned, NovaDerm is well positioned to enter and successfully complete the clinical trials for FDA product approval. Currently, our main task is to raise the adequate funding to complete the IND application and begin the clinical trials, which we estimate at $3.5 million to $4.5 million.
https://www.sec.gov/Archives/edgar/data/1412659/000166225218000034/rgin10q.htm
That big trade is possibly a Broadsmoore or Omniview (a la Discala, see FBI and SEC indictments etc) holding being lightened. Or Randy having a creditor on his back perhaps....
That stem cell product looks interesting though, from a couple of posts back.
Eventually a Q will surface detailing the news maaaaaaaaaaaybe a pr costing a 8k or just a 8k. A quick glance at their filings and its rearranged numbers not amounting to too much since
McCoy is following his dream
whats not to love
Thanks, I bought back in.
No idea, someone has been hawking for months about a funding deal coming. No official word from McCoy anywhere. He could take a lesson in communications from Rubakh but apparently he has a disdain for retail shareholders.
I know McCoy has some pissed off Windstar shareholders from ions ago.
Anybody know what was behind all that volume on 2/22? Nearly 3 Million and it shows as accumulation on the chart, but no real upward movement. What's up with that?
http://stockcharts.com/h-sc/ui?s=RGIN&p=D&yr=1&mn=6&dy=0&id=p08957588467
This thing is dead in the water and sinking fast
Maybe someday RGIN shareholders will get a PR like their competitor
RenovaCare, Inc., (RCAR), developer of the SkinGun™ and CellMist™ System for spraying a patient’s own skin stem cells onto burns and wounds for rapid self-healing, today announced new initiatives to expand its product pipeline and associated clinical indications beyond severe second-degree burns.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180226006027/en/
The Company’s expansion program follows recent patent awards and positive FDA feedback on its breakthrough stem cell spray technology, currently on exhibit at the prestigious Science Museum in London, England.
Righto Randall/Nicole. Promise number 89.
Good Volume for a Thursday in Regenicin land. Will Nicoles premonitions bear any fruit?
Looks like someone unloaded a position though
https://ih.advfn.com/stock-market/USOTC/regenicin-inc-pc-RGIN/trades
Maybe Nicole is cashing in roadside cans, she has been screaming funding coming for 2-3 months now. I didnt bother reading the Q, the share price tells me all I need to know.
GLTY and find a nice crypto miner if youre serious about making coin.
Just a photocopy of the last 20 odd quarterly reports. Things look great, world changing product, just that we have lost another $200k and only have $7k in cash left, but J&J will realise what we have soon......
i.e. they have nothing but a scheme to make money from suckers.
OK...Now What? They say they need $$$
Ammended Annual Report(period ending Sep 2017) filed with AUDITED reports.
Audited reports?hmmmmm
http://quicktake.morningstar.com/StockNet/SECDocuments.aspx?Symbol=RGIN
What will it take to get RGIN to $2.00?
I see that last post refers to a purported speech about Novaderms success. Implies it is already on sale, when in fact it is still way way pre-clinical trial, that is to say - at best, years away from being for sale, IND status or not. The session is by the guy who is Pure Med Farmas marketing guy, i.e. has strong links to McCoy who is a shareholder in PMF.
How surprising, more smoke and mirrors.
if i am reading correctly if Amarantus decide to license Novaderm then RGIN doesn't get much other than $10M and 5% royalty on after $150m gross.
Correct me if i amwrong.
'In addition, Amarantus received an exclusive, five (5) year option to license any severe burn-related products developed by Regenicin. Amrantus can exercise this option at a cost of $10,000,000 USD plus a royalty of 5% on gross revenues in excess of $150M USD.'
https://www.sec.gov/Archives/edgar/data/1424812/000114420414069314/v394587_8k.htm
Followers
|
71
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2931
|
Created
|
08/06/10
|
Type
|
Free
|
Moderators |
Regenicin, Inc.
10 High Court
Little Falls, NJ 07424
**updated and correct phone number** (973) 557-8914
they filed this on aug 22 2016- http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11558959
Name: | Randall McCoy |
Title: | Principal Executive Officer and Director |
Date: | August 22, 2016 |
Name: | John J. Weber |
Title: | Principal Financial Officer and Director |
Date: | August 22, 2016 |
LITTLE FALLS, N.J., June 12, 2012 /PRNewswire/ -- Regenicin, Inc. (OTC Bulletin Board: RGIN) a biotechnology company specializing in the development of and commercialization of regenerative cell therapies to restore the health of damaged tissues and organs, announced today that the Food and Drug Administration (FDA) has granted Orphan Status approval for the PermaDerm® product, the only tissue-engineered skin prepared from autologous (patient's own) skin cells consisting of both epidermal and dermal layers, that is indicated for catastrophic burn patients. The FDA had previously designated PermaDerm® to be a biological/drug (permanent skin replacement) not a medical device (temporary skin replacement). PermaDerm® is the only skin replacement technology to receive this Biological/drug designation.
COMPANY HIGHLIGHTS:
PermaDerm™ is being developed to be the only tissue-engineered skin prepared from autologous (patient's own) skin cells consisting of both epidermal and dermal layers. A small harvested section of the patient's own skin can be grown to graft an area one hundred times its size in as little as thirty days.
These living, self-to-self skin graft tissue are intended to form permanent skin tissue that will not be rejected by the immune system of the patient, a critical possibility in porcine or cadaver skin grafts used today.
The technology has been clinically tested in over 150 pediatric, catastrophic burn patients. Currently Regenicin is working with its contract manufacturer to prepare for pre-market approval of PermaDerm™ from the FDA.
PermaDerm™ is being designed to save lives, reduce healthcare costs by decreasing the patient's stay in the Critical Care Unit and reduce the need for additional surgeries. An insurance company procedural code has been approved for reimbursement of costs to hospitals. The American Medical Association has assigned CPT (Current Procedural Terminology) code for cultured skin substitutes under the dermal substitute category which enables insurance companies to process and hospitals to be reimbursed for cultured skin substitutes once approved by the FDA.
According to the American Burn Association, there are currently over 2,000 cases annually involving burns covering over 50% of the patient's total body surface area.
PermaDerm™ is being developed for the treatment of catastrophic, full-thickness burns covering over 50% of the total body surface area.
PermaDerm™ has been used in clinical trials on pediatric patients with catastrophic burns covering from 50 to 90+% of their body.
PermaDerm™ is being developed to require less donor skin from the patient's own body, thus needing fewer surgeries to harvest skin. The result is expected to be less scarring, with fewer infections and faster healing.
Randall McCoy
Chief Executive Officer
Randall McCoy has more than 37 years of experience in the healthcare industry. His experience includes executive positions and scientific research and development. His previous employment includes George Washington University, Temple University Medical School and RCA/SRI International (Director of Life Sciences and Electronic Displays). Mr. McCoy has assisted both small and major pharmaceutical/device companies address FDA issues. He has also helped over 225 foreign and domestic companies introduce their FDA regulated drug and medical device products into the US and World market. Mr. McCoy currently has over 30 Patents US and International.
Changed to AMBS
Dr. Joseph Rubinfeld Ph.D
Director at CytRX; Initial Co-Founder of Amgen, Inc.
Dr. Joseph Rubinfeld co-founded SuperGen, Inc. in 1991 and has served as its Chief Executive Officer and President, Chief Scientific Officer and as a director. He has been a director of CytRX since July 2002. Dr. Rubinfeld is also a founder of JJ Pharma. Dr. Rubinfeld was one of the four initial founders of Amgen, Inc. in 1980 and served as a Vice President and its Chief of Operations until 1983. From 1987 until 1990, Dr. Rubinfeld was a Senior Director at Cetus Corporation and from 1968 to 1980, Dr. Rubinfeld was employed at Bristol-Myers Company. Dr. Rubinfeld received a B.S. degree in chemistry from C.C.N.Y. and an M.A. and Ph.D in chemistry from Columbia University.
John Weber
Regenicin™'s Interim CFO
John Weber most recently served as Executive Vice President of Fujifilm USA, the highest ranked American corporate officer, from 2006 until his departure in 2009. His responsibilities included overseeing all corporate activity with the exception of R&D. During that time Fujifilm was ranked as the fastest growing medical imaging company, consistently ranking #1 or #2 in customer satisfaction. From 1998 through 2006 he served as Senior Vice President, Operations at Fujifilm USA where he spearheaded the transition of the company from a film distributor to a digital medical informatics company. From 1986 until 1998 he served as CFO where he helped to profitably manage Fuji's growth from an employee base of 75 to over 1,000. Prior to his distinguished career at Fujifilm USA, Mr. Weber served as the CFO for the confectionary and drinks division of Cadbury Schweppes Limited for three years and as Corporate Controller for an additional five years.
Dr. Craig Eagle
Pfizer Oncology
Dr. Craig Eagle joined Pfizer Australia in 2001 as part of the medical group. In Australia, his role involved leading and participating in scientific research, regulatory and pricing & re-imbursement negotiations for compounds in therapeutic areas including oncology, anti-infectives, respiratory, arthritis and pain management. In 2003, Pfizer relocated Dr. Eagle to the United States where he was appointed as the worldwide lead for development of Celecoxib in oncology to oversee the global research program. Since that time he has had increasing responsibility for overseeing the global research plans and teams for Irinotecan and Dalteparin. In 2007, he became head of Medical Affairs and Outcomes Research for Pfizer, including the US oncology business. Dr. Eagle has led, or been directly involved with, teams that resulted in eight new products or indications. As part of his current role at Pfizer, he has led the integration of the Pfizer/Wyeth oncology businesses and portfolio.
The Broadsmoore Group, LLC 9,223,770(8)
560 Lexington Ave., 16 th Fl.
New York, NY 10022
PDA Associates LLC 7,770,000(9)
560 Lexington Ave., 16 th Fl.
New York, NY 10022
Officers, directors and 5 percent shareholders collectively 54,508,099(10) 59.74%
* Less than 1%
(1) Unless otherwise indicated, each person or entity named in the table has sole voting power and investment power (or shares that power with that person's spouse) with respect to all shares of common stock listed as owned by that person or entity.
(2) A total of 83,807,964 shares of the Company's common stock are considered to be outstanding pursuant to Rule 13d-3(d)(1) under the Securities Exchange Act of 1934.
(3) Includes 32,821,641 shares of common stock held in his name and options to purchase 885,672 shares of common stock.
(4) Includes 50,000 shares of common stock held in his name and options to purchase 885,672 shares of common stock,
(5) Includes 1,050,000 shares of common stock held in his name and options to purchase 885,672 shares of common stock
(6) Includes 50,000 shares of common stock held in his name and options to purchase 885,672 shares of common stock,
(7) Includes 33,971,641 shares of common stock, options to purchase 3,542,688 shares of common stock and shares of Series A Convertible Preferred Stock convertible into 3,350,000 shares of common stock,
(8) Includes 5,706,270 shares of common stock held in its name, warrants to purchase 167,500 shares of common stock and shares of Series A Convertible Preferred Stock convertible into 3,350,000 shares of common stock,
(9) Includes 7,400,000 shares of common stock held in its name and warrants to purchase 370,000 shares of common stock,
(10) Includes 47,077,911 shares of common stock, warrants to purchase 537,500 shares of common stock, options to purchase 3,542,688 shares of common stock and shares of Series A Convertible Preferred Stock convertible into 3,350,000 shares of common stock
http://ih.advfn.com/p.php?pid=nmona&article=5144097
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |